All News

psA.fil_.Hands_.jpg

ICYMI: Bimekizumab is Coming…in Third Place

d Michael Putman, MD, MSCI

Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and the U.S. for psoriasis. That makes this the year I plan to figure out where this drug will be useful for my patients with PsA. 

Read Article
am pm pillbox containing pills in each slot

ICYMI: Methotrexate: shall we split up?

d Aurelie Najm, MD, PhD

Methotrexate is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg. In the SMART study, Prasad et al. present the first RCT comparing either single dose (25 mg) or split-dose (10 mg morning, 15 mg evening, same day) once weekly MTX for 24 weeks.

Read Article
acr_session2.jpeg

ICYMI: ACR Plenaries: Changing the Practice of Rheumatology

d Kathryn H. Dao, M.D.

Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.

Read Article
pregnant.baby_.hands_.jpg

ICYMI: Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases

d Bella Mehta, MBBS, MS

Pregnant women with autoimmune rheumatic diseases (ARDs) and antiphospholipid syndrome (APS) face significantly increased risks of cardiovascular events (CVEs). This increased risk is often attributed to ARDs, its medications or comorbidities associated with it.

Read Article
Fatigue,depression

EULAR 2023 Recommendations on Fatigue

d Jack Cush, MD

Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life. A EULAR task force set out to develop recommendations for the management of fatigue in people with I-RMDs.

Read Article

IL-18 excess is assoc. w/ autoinflammatory Dz, "IL-18opathies". High IL-18 associated w/ #MAS & PSTPIP1-related diseases (eg, PAPA syndr. Pyogenic arthritis, pyoderma gangrenosum, acne)IL-18 binding protein is a biomarker of IFNγ activity. https://t.co/dy3xHdgTXX https://t.co/qBvCHvtsu7

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA undergoing lumbar degenerative disease (LDD) surgery have 2 fold higher risk of VTE. National Inpatient study 471,283 LDD surgeries showed PsA had higher overall morbidity (9 % v 7 %), VTE (1.4 % v 0.7 %), unfavorable D/C(21% v. 17 %). https://t.co/C0eimmwEmm https://t.co/58PoJOJEeY

Links:

Dr. John Cush RheumNow ( View Tweet)
RA pts more likely to get autoimmune thyroid Dz (AITD), but after dx, AITD risk signif. drops (HR 0.81), suggesting RA Rx lowers AITD risk; greater drop in biologic Rx RA (HR 0.54).Swiss registry compared 13,731 new-onset RA pts to 63,201 matched controls https://t.co/n0n2EfUyqR https://t.co/yMMHvYRsyY

Links:

Dr. John Cush RheumNow ( View Tweet)
Cannabis Use in Rheumatic Diseases Dr. Janet Pope discusses several abstracts presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/C2vbbERoHZ https://t.co/XeiS0cJjuy

Links:

Dr. John Cush RheumNow ( View Tweet)
INVIGORATE-1 Study: IV Secukinumab for Treatment of Active axSpA Dr. Atul Deodhar reports on abstract 2545 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/Fhv7dhDTJA https://t.co/Zz0PwFjOD4

Links:

Dr. John Cush RheumNow ( View Tweet)
CDC: Chronic Fatigue Syndrome 2021-2022 The current CDC report estimates that 1.3% of adults had myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), based on the most recent population based National Health Interview Survey (NHIS 2021–2022). https://t.co/4LeQ7DJPyI https://t.co/5ITG46d25M

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. https://t.co/rNSTcT5O6L https://t.co/f5lvMTH7ik

Links:

Dr. John Cush RheumNow ( View Tweet)
The ARGO Project for Rheumatology Fellows Dr. Sheila Reyes (Philippines) talks with Dr. Lisa Traboco about abstract 2078, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/RRjc38JpEQ https://t.co/q9rCxbWzNh

Links:

Dr. John Cush RheumNow ( View Tweet)
When should we be starting therapy in GCA and PMR? The problem with having therapies that work is that you then have to figure out what to do with them. You cannot hide behind the ambiguity of therapeutic inadequacy. https://t.co/oRWTeH5Q9h https://t.co/BbswdffoKM

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date for RheumNow Live 2024, on January 27-28, in Dallas, TX, or from the comfort of your own space through our virtual platform! Why choose RheumNow Live? Because this isn't just another conference – it's a revolution in medical education! https://t.co/K2YYqjjs8F https://t.co/MinRm9N9rz

Links:

Dr. John Cush RheumNow ( View Tweet)
Health disparities in SLE reviewed disparities by Parodis et al. Racial and ethnic influences on manifestations and outcomes reviewed, along with common pitfalls in studies, along w/ proposed framework for research on health disparities in SLE (full read) https://t.co/7GvzttR9HZ https://t.co/wYGiMg4zqK

Links:

Dr. John Cush RheumNow ( View Tweet)
Promising Therapies for Sjogren's Dr. Yuz Yusof discusses abstracts 1634 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/8iSDMKtKwa https://t.co/QCYTnpYKFN

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: SpA Sleuths: The Case of Undiagnosed IBD As rheumatologists, we are medical detectives investigating complex and often elusive autoimmune and inflammatory conditions https://t.co/dE0NLXKDvT https://t.co/DalUXRf3MB

Links:

Dr. John Cush RheumNow ( View Tweet)
CBT or Naltrexone in Fibromyalgia https://t.co/9SGRbY97oD https://t.co/wN2cMuqgHa

Links:

Dr. John Cush RheumNow ( View Tweet)
Expert consensus(ASAS) prefers SpondyloArthritis(axSpA) as preferred over "ankylosing spondylitis" (historic but no longer appropriate based on MRI research showing this is more than SI disease). AS radiographic axSpA(r-axSpA) can be used interchangeably https://t.co/jvT3lQFaPq https://t.co/WRNrbfjK1S

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×